You are here: Industry Insights > Novo Nordisk

News List

More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. worldpharmanews
September 13, 2017
A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments.
Novo Nordisk resolves US federal investigation into marketing practices pharmatimes
September 07, 2017
Novo Nordisk has said it has reached a resolution with the US federal government and the states about an investigation launched in February 2011 concerning sales and marketing practices for Victoza,
Novo Nordisk settles lawsuit over illegal marketing practices for $58.7 million pharmafile
September 07, 2017
Novo Nordisk has resolved a probe by the US Justice Department which accused the Danish drugmaker of illegal marketing activities in the sale of its top selling product Victoza and other drugs from its diabetes portfolio.
Victoza® reduces the risk of major cardiovascular events in people with type 2 diabetes with or with worldpharmanews
August 29, 2017
Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of their history of having a heart attack and/or stroke or not having any of these events, when compared to placeb
Victoza's triple-play CV nod sharpens Novo's edge against Trulicity fiercepharma
August 29, 2017
Victoza's new cardiovascular benefit approval gives it an edge over its new rival from Eli Lilly, Trulicity.
Chutes & Ladders—Novartis lures UCSF cardiovascular scientist Coughlin fiercebiotech
August 21, 2017
UCSF cardiovascular scientist Shaun Coughlin left for the Novartis Institutes for BioMedical Research to head up CV and metabolism R&D.
Novo Nordisk's new semaglutide trounces Lilly's scrappy Trulicity in diabetes trial fiercepharma
August 18, 2017
Novo Nordisk is counting on semaglutide, its forthcoming GLP-1 diabetes drug, to drive growth over the next few years, and data from the trial Sustain-7 should help.
Novo diabetes drug outperforms Lilly rival at Phase 3 pharmafile
August 18, 2017
Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling glucose levels and promoting weight loss in patients with the ...
Novo Nordisk CEO: Don't scapegoat pricing pressure. Better drugs grow anyway fiercepharma
August 10, 2017
Novo Nordisk CEO Lars Fruergaard Jorgensen said the company's portfolio will help it grow amid pricing challenges.
Oral insulin could still be a reality, says Novo Nordisk pharmaphorum
June 15, 2017
Last October Novo Nordisk announced that it had shelved plans to bring the world’s first oral insulin to market .

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page